5-cyano-1-methylindole-2-carboxylic acid | 194163-02-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-cyano-1-methylindole-2-carboxylic acid
• CAS: 194163-02-5
• 化学式: C₁₁H₈N₂O₂
• 分子量: 200.197
• InChiKey: UPQWWWSWVOIMMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-cyano-1-methylindole-2-carboxylic acid 在 盐酸 、 4-二甲氨基吡啶 、 lithium hydroxide 、 乙醇 、 氨 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 88.0h， 生成 7-[(5-Carbamimidoyl-1-methyl-1H-indole-2-carbonyl)-amino]-heptanoic acid
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k
• 作为产物：
  描述：

  methyl-1-methyl-5-cyanoindole-2-carboxylate 在 LiOH 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 5-cyano-1-methylindole-2-carboxylic acid
  参考文献：
  名称：

  5,6-Bicyclic glycoprotein IIb IIIa antagonists useful in inhibition of platelet aggregation

  摘要：

  这项发明涉及5,6融合环双环化合物，包括吲哚、苯并呋喃和苯并噻吩，并对应于配有基本（B）和酸性（A）功能的化学式（I），这些化合物在抑制血小板聚集方面具有用途。

  公开号：

  EP0655439A3

文献信息

• 5,6-Bicyclic glycoprotein IIb IIIa antagonists useful in inhibition of platelet aggregation
  申请人：ELI LILLY AND COMPANY

  公开号：EP0655439A3

  公开（公告）日：1997-10-08

  This invention relates to 5,6 fused ring bicyclic compounds inclusive of indoles, benzofurans, and benzothiophenes, and corresponding to the formula (I) substituted with both basic (B) and acidic (A) functionality, which are useful in inhibition of platelet aggregation.

  这项发明涉及5,6融合环双环化合物，包括吲哚、苯并呋喃和苯并噻吩，并对应于配有基本（B）和酸性（A）功能的化学式（I），这些化合物在抑制血小板聚集方面具有用途。
• [EN] PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RECEPTEURS ACTIVES PAR LES PROLIFERATEURS DE PEROXYSOMES
  申请人：LILLY CO ELI

  公开号：WO2005054176A1

  公开（公告）日：2005-06-16

  The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种式（I）的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，可用于治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖、凝血障碍、高血压、动脉粥样硬化以及其他与X综合征和心血管疾病相关的疾病。
• [EN] N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE N-CYCLYL-3-(CYCLYLCARBONYLAMINOMÉTHYL)BENZAMIDE EN TANT QU'INHIBITEURS DE LA RHO KINASE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012006203A1

  公开（公告）日：2012-01-12

  The present invention relates to compounds of formula (I) : and pharmaceutically acceptable salts thereof, wherein R1and R2 are various ring systems. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of Rho Kinase mediated diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及化合物的公式（I）及其药学上可接受的盐，其中R1和R2是不同的环系统。该发明还涉及包括这些化合物的药物组合物，使用这些化合物治疗Rho激酶介导的疾病和障碍的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• Peroxisome proliferator activated receptor modulators
  申请人：Canada Jane Emily

  公开号：US20070082907A1

  公开（公告）日：2007-04-12

  The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种式（I）的化合物，或其药学上可接受的盐、溶剂水合物或立体异构体，其可用于治疗或预防由过氧化物酶体增殖激活受体（PPAR）介导的疾病，例如X综合征、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉硬化和其他与X综合征和心血管疾病相关的疾病。
• 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Goerlitzer Jochen

  公开号：US20080249126A1

  公开（公告）日：2008-10-09

  The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved.

  本发明涉及具有酸性、大多数为杂环基团的1,3-取代环烷衍生物及其生理上可接受的盐和生理上功能性衍生物。所描述的是式I的化合物，其中基团如定义所述，以及它们的生理上可接受的盐和制备它们的方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及涉及胰岛素抵抗的紊乱。